

EN
E-000071/2026
Answer given by Mr Várhelyi
on behalf of the European Commission
(16.3.2026)

The Joint Research Centre has carried out significant work on plants obtained by certain new genomic techniques (NGTs), e.g. on scientific aspects and state-of-the-art analysis in relation to market access¹ and on case studies². While the state-of-the-art analysis in relation to market access provided a comprehensive review of market applications of NGTs, it does not contain the molecular data that is necessary to assess whether a specific NGT plant would be a category 1 or in category 2, as in many cases the necessary information is not publicly available. Therefore, the Commission cannot provide an estimate, based on the work of the Joint Research Centre, of what percentage of NGT plants would fall into category 1 according to the criteria of equivalence of NGT plants to conventional plants as agreed between the European Parliament and the Council in the provisional political agreement of 3 December 2025.

¹ New genomic techniques – State-of-the-art review, Publications Office, 2021,
<https://data.europa.eu/doi/10.2760/710056>.

Current and future market applications of new genomic techniques, Publications Office, 2021,
<https://data.europa.eu/doi/10.2760/02472>.

² <https://publications.jrc.ec.europa.eu/repository/handle/JRC131721>.
<https://publications.jrc.ec.europa.eu/repository/handle/JRC131711>.